Sandrine Puverel

1.5k total citations
29 papers, 988 citations indexed

About

Sandrine Puverel is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Sandrine Puverel has authored 29 papers receiving a total of 988 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 12 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Sandrine Puverel's work include Lymphoma Diagnosis and Treatment (12 papers), CAR-T cell therapy research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Sandrine Puverel is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), CAR-T cell therapy research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Sandrine Puverel collaborates with scholars based in United States, Monaco and France. Sandrine Puverel's co-authors include Denis Allemand, Didier Zoccola, Éric Tambutté, Sylvie Tambutté, Fanny Houlbrèque, Stéphanie Reynaud, Christine Ferrier‐Pagès, Paola Furla, Lino Tessarollo and Jean‐Claude Scimeca and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Cell Biology and Blood.

In The Last Decade

Sandrine Puverel

26 papers receiving 967 citations

Peers

Countries citing papers authored by Sandrine Puverel

Since Specialization

Citations

This map shows the geographic impact of Sandrine Puverel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandrine Puverel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandrine Puverel more than expected).

Fields of papers citing papers by Sandrine Puverel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandrine Puverel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandrine Puverel. The network helps show where Sandrine Puverel may publish in the future.

Co-authorship network of co-authors of Sandrine Puverel

This figure shows the co-authorship network connecting the top 25 collaborators of Sandrine Puverel. A scholar is included among the top collaborators of Sandrine Puverel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandrine Puverel. Sandrine Puverel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Matthew Mei, Lu Chen, Sandrine Puverel, Robert Chen, Leslie Popplewell, Liana Nikolaenko, (unknown), Saro H. Armenian, Larry W. Kwak, Steven T. Rosen, Stephen J. Forman, Alex F. Herrera	0
2	Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease 2024 ·Blood ·(unknown), John H. Baird, Lu Chen, Joo Y. Song, Xiuli Wang, (unknown), (unknown), (unknown), (unknown), Zhenyuan Dong, Teresa S. Kim, (unknown), Sandrine Puverel, (unknown), (unknown), Stephen J. Forman, Larry W. Kwak, Lihua E. Budde	0
3	PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease. 2024 ·Journal of Clinical Oncology ·Lihua E. Budde, (unknown), John H. Baird, Lu Chen, Joo Y. Song, Xiuli Wang, (unknown), (unknown), Teresa S. Kim, (unknown), (unknown), Min Guan, (unknown), Sandrine Puverel, Katrin Tiemann, Hazel Cheng, Stephen J. Forman, Larry W. Kwak, Ibrahim Aldoss	1
4	Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study 2024 ·The Lancet Haematology ·Alex F. Herrera, Jasmine Zain, Kerry J. Savage, Tatyana Feldman, Jonathan E. Brammer, Lu Chen, Sandrine Puverel, Leslie Popplewell, Lihua E. Budde, Matthew Mei, Chitra Hosing, Ranjit Nair, Lori A. Leslie, (unknown), (unknown), Stephen J. Forman, Steven T. Rosen, Larry W. Kwak, Swaminathan P. Iyer	10
5	Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma 2023 ·Haematologica ·James Godfrey, Matthew Mei, Lu Chen, Joo Y. Song, Victoria Bedell, Lihua E. Budde, Saro H. Armenian, Sandrine Puverel, Liana Nikolaenko, Robert Chen, (unknown), (unknown), (unknown), Steven T. Rosen, Stephen J. Forman, Leslie Popplewell, Larry W. Kwak, Alex F. Herrera	10
6	A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL) 2022 ·Blood ·Geoffrey Shouse, Tanya Siddiqi, Leslie Popplewell, (unknown), (unknown), (unknown), (unknown), Sandrine Puverel, Lili Wang, Adam S. Kittai, Lu Chen, Matthew S. Davids, Alexey V. Danilov	5
7	Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma 2022 ·Blood ·(unknown), Matthew Mei, Lu Chen, Sandrine Puverel, Robert Chen, Leslie Popplewell, Liana Nikolaenko, (unknown), Saro H. Armenian, Larry W. Kwak, Steven T. Rosen, Stephen J. Forman, Alex F. Herrera	1
8	A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL) 2021 ·Blood ·Geoffrey Shouse, Tanya Siddiqi, Leslie Popplewell, (unknown), (unknown), (unknown), (unknown), Sandrine Puverel, Lili Wang, Adam S. Kittai, Lu Chen, Matthew S. Davids, Alexey V. Danilov	4
9	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma 2019 ·Clinical Cancer Research ·Robert Chen, Alex F. Herrera, (unknown), Lu Chen, Jun Wu, (unknown), Timothy W. Synold, Vu N. Ngo, Sandrine Puverel, Matthew Mei, Leslie Popplewell, Shuhua Yi, Joo Y. Song, Shu Tao, Xiwei Wu, Wing C. Chan, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Edward M. Newman	61
10	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies 2019 ·Leukemia & lymphoma ·Tanya Siddiqi, Paul Frankel, Jan H. Beumer, Brian F. Kiesel, Susan M. Christner, (unknown), Joo Y. Song, Robert Chen, Kevin R. Kelly, Sikander Ailawadhi, Paul Kaesberg, Leslie Popplewell, Sandrine Puverel, Richard Piekarz, Stephen J. Forman, Edward M. Newman	22
11	RanBPM (RanBP9) regulates mouse c-Kit receptor level and is essential for normal development of bone marrow progenitor cells 2016 ·Oncotarget ·Sandrine Puverel, Erkan Kiris, Satyendra Kumar Singh, Kimberly D. Klarmann, Vincenzo Coppola, Jonathan R. Keller, Lino Tessarollo	9
12	BDNF modulates heart contraction force and long-term homeostasis through truncated TrkB.T1 receptor activation 2015 ·The Journal of Cell Biology ·Gianluca Fulgenzi, Francesco Tomassoni‐Ardori, Lucia Babini, Jodi Becker, Colleen Barrick, Sandrine Puverel, Lino Tessarollo	77
13	RanBPM, a Scaffolding Protein for Gametogenesis 2012 ·Current topics in developmental biology ·Sandrine Puverel, Lino Tessarollo	3
14	Prokineticin receptor 2 expression identifies migrating neuroblasts and their subventricular zone transient‐amplifying progenitors in adult mice 2008 ·The Journal of Comparative Neurology ·Sandrine Puverel, Hiroko Nakatani, Carlos Parras, Nadia Soussi‐Yanicostas	24
15	Evidence of low molecular weight components in the organic matrix of the reef building coral, Stylophora pistillata 2007 ·Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology ·Sandrine Puverel, Fanny Houlbrèque, Éric Tambutté, Didier Zoccola, P. Payan, (unknown), Sylvie Tambutté, Denis Allemand	13
16	Soluble organic matrix of two Scleractinian corals: Partial and comparative analysis 2005 ·Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology ·Sandrine Puverel, Éric Tambutté, Lucilia Pereira Mouriès, Didier Zoccola, Denis Allemand, Sylvie Tambutté	74
17	Ca²⁺‐dependent lipid binding and membrane integration of PopA, a harpin‐like elicitor of the hypersensitive response in tobacco 2005 ·Molecular Microbiology ·Judith Racapé, Lassaâd Belbahri, Stefan Engelhardt, Benoı̂t Lacombe, (unknown), Jan Lochman, (unknown), Michel Nicole, Thorsten Nürnberger, Francis Parlange, Sandrine Puverel, Harald Keller	43
18	Molecular cloning and localization of a PMCA P-type calcium ATPase from the coral Stylophora pistillata 2004 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·Didier Zoccola, Éric Tambutté, (unknown), Sandrine Puverel, Jean‐Claude Scimeca, Denis Allemand, Sylvie Tambutté	147
19	Biomineralisation in reef-building corals: from molecular mechanisms to environmental control 2004 ·Comptes Rendus Palevol ·Denis Allemand, Christine Ferrier‐Pagès, Paola Furla, Fanny Houlbrèque, Sandrine Puverel, Stéphanie Reynaud, Éric Tambutté, Sylvie Tambutté, Didier Zoccola	275
20	Antibodies against the organic matrix in scleractinians: a new tool to study coral biomineralization 2004 ·Coral Reefs ·Sandrine Puverel, (unknown), Didier Zoccola, Isabelle Domart‐Coulon, A Bouchot, (unknown), Denis Allemand, (unknown)	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact